Since further analyses could not be performed due to the insufficient number of existing studies, current data led us to a speculation that AGR2 might truly function as a tumour suppressor in some tumour types19, which however awaited future experimental verifications, especially in lung cancer, prostate cancer, ovarian cancer, gastric cancer, and colorectal cancer. This evidence concerns the gene AGR2 and ovarian carcinoma.